https://www.edaily.co.kr/news/read?newsId=02341926596481144&mediaCodeNo=257&OutLnkChk=Y 

https://www.edaily.co.kr/news/read?newsId=01462886599532528&mediaCodeNo=257&OutLnkChk=Y 

I, Korea’s leading pharmaceutical company has challenged against the patent for allergic rhinitis treatment owned by S, a multinational pharmaceutical company. The above patent is a medical use invention that the effect of the active ingredients is limited and the usage and dosage is limited as well as the active ingredients. AIP, which represented this case contributed to invalidating the applicable patent by developing and presenting an argument to the court whether limiting the effect of the active ingredients and the usage and dosage in a medical use invention could be a configuration of an invention, and if so, how inventive step should be determined. In the argument, AIP also presented the standard in determining how much prior invention should disclose in order to deny inventive step in medical use invention.